FORMATION OF GROUP RISK IN BREAST CANCER PATIENTS REGARDING TO DISTINCTIVE MEDICAL AND GENETIC FACTORS IN WOMEN OF ALTAI REGION

Epidemiology of breast cancer (BC) is the most studied, not only because of the high incidence of this tumor, but also of the significant aesthetic and social importance of this organ for women [2,5]. The incidence of breast cancer holds a leading place for more than 20 years in the structure of cancer pathology in women in the Russian Federation and in the Altai region [5,8]. There are no trends in decreasing of morbidity: in 2002 in the Russian Federation this parameter was 38.89 per 100 thousand (%ooo, standardized parameter), in 2012 - 46.17%ooo (increase during past 10 years - 19.94%) [5]. There is the same trend in the Altai region: the growth of "rough" parameter of the incidence of breast cancer in the period 2004-2012 was 28.2%, the standardized parameter - 46.76%ooo in 2012 [5]. Breast cancer - one of the 3 malignant neoplasms (MN) which is designed for mammography screening, which significantly reduces the mortality from this MN in women aged 50-69 years [2,7,9,15]. Today, multiple risk factors are studied and identified enabling the development of oncological risk group, which aims is the prevention and early diagnosis of breast cancer [1,3,6,12,19,23]. It is proved that up to 10% of malignant breast tumors are genetically determined and, perhaps, the most of molecular genetic studies in oncology are focused on breast cancer problems [10,13,14,16,17,24]. At the same time, despite the many advances in the prevention and diagnosis of this disease, the high levels of mortality are stably maintained. Mortality from breast cancer in the Altai region in 2013 was 28.1%ooo (in the Russian Federation in 2012 - 29.8%ooo) [5]. Thus, the problem of prevention of malignant tumors of the breast is not yet resolved and remains extremely relevant.

1. Берштейн Л. М., Факова Р. М., Цырлина Е. В., Крюкова О. Г., Порошина Т. Е., Семиглазов В. В. Особенности гормональнометаболических нарушений у больных с основными биологическими подтипами рака молочной железы / Евразийский онкологический журнал 3 (03) 2014 // Тезисы VIII съезда онкологов и радиологов СНГ и Евразии 16–18 сентября 2014 года. C 243–244.

2. Заридзе Д. Г. Профилактика рака. Руководство для врачей. — М.: ИМА-ПРЕСС, 2009. —224 с.

3. Имянитов Е. Н., Хансон К. П. Молекулярная онкология: клинические аспекты. С-Петербург: Печатный дом МАПО. — 2007. — 210 с.

4. Имянитов Е. Н. Скрининг для лиц с наследственной предрасположенностью к раку // Практическая онкология — Т. 11, № 2–2010, С 102–107.

5. Под редакцией А. Д. Каприна, В. В. Старинского,Г. В. Петровой Злокачественные новообразования в России в 2012 году (заболеваемость и смертность) — М.: ФГБУ «МНИОИ им. П. А. Герцена» Минздрава России. — 2014. — 250 с.

6. Кулигина Е. Ш. Эпидемиологические и молекулярные аспекты рака молочной железы / Практическая онкология — Т. 11, № 4–2010, С. 203–216.

7. Онкология. Национальное руководство. Краткое издание /под ред акад. РАМН В. И. Чиссова, акад/ РАН и РАМН М. И. Давыдова. — М.: ГЭОТАР-Медиа, 2013. —576 с.

8. Писарева Л. Ф. Заболеваемость раком молочной железы женского населения Иркутской области. Факторы риска / Л. Ф. Писарева [и др.] // Сибирский онкологический журнал. — 2012. — № 5 (53).— С. 12–17.

9. Руководство по медицинской профилактике / Под. ред. Р. Г. Оганова, Р. А. Хальфина. — М.: ГЭОТАР-Медиа, 2007. — 464 с.

10. Abecasis G. R., Auton A., Brooks L. D. et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491 (7422): 56–65.

11. Boyarskikh U. A., Zarubina N. A., Biltueva J. A., Sinkina T. V., Voronina E. N., Lazarev A. F., Petrova V. D., Aulchenko Y. S., Filipenko M. L. Association of FGFR2 gene polymorphisms with the risk of breast cancer in population of West Siberia // Europian Journal of Human Genetics (2009), 1–4.

12. Clemons M. and Goss P. Estrogen and the risk of breast cancer // N. Engl. J. Med. — 2001. — Vol. 344. — P.276–285.

13. De Leeneer K., Hellemans J., De Schrijver J. et al. Massive parallel amplicon sequencing of the breast cancer genes BRCA1 and BRCA2: opportunities, challenges, and limitations. Hum. Mutat. 2011; 32 (3): 335–344.

14. Garcia-Closas M., Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status // Clin Cancer Res. — 2008. — Vol.14, № 2. — P.8000–800910.

15. IARC. Breast cancer screening / IARC Handbook of Cancer Prevention. Lyon: International Agency for Research on Cancer, 2002.

16. Imyanitov E. N. and Hanson K. P. Mechanisms of breast cancer // Drug discovery today: Disease mechanisms. — 2004. — Vol.1, № 2. — P.235–245.

17. Knudson A. G. Cancer genetics // Amer. J. Med. Genet. — 2002. — Vol.111. — P.96–102.

18. Lazarev A. F., Petrova V. D., Terekhova S. A. et al. Factor analysis in early detection of malignancies //2006 ASCO Annual Meeting Proceedings, Suppl. to Journal of Clinical Oncology, Vol. 24, No.18S, June 20, 2006,57 s.

19. McPherson K. et al.ABC of breast diseases. Breast cancerepidemiology, risk factors, and genetics // Brit. Med. J. — 2000– Vol.321. — P.624–628.

20. Michils G., Hollants S., Dehaspe L. et al. Molecular analysis of the breast cancer genes BRCA1 and BRCA2 using amplicon-based massive parallel pyrosequencing. J. Mol. Diagn. 2012; 14 (6): 623–630.

21. Morgan J. E., Carr I. M., Sheridan E. et al. Genetic diagnosis of familial breast cancer using clonal sequencing. Hum. Mutat. 2010; 31 (4): 484–491.

22. Petrova V. D., Sinkina T. V., Zarubina N. A., Terekhova S. A., Dimitriadi J. N., Selezneva I. A., Lazarev A. F. Alqorithm of monitoring of patients with family history of cancer as a method of cancer prevention // 43rd Annual Meeting of American Society of Clinical Oncology. — Chicago, Illinois, June 1–5, 2007. — 2007 Annual Meeting Proceedings Part I (a supplement to the Journal of Clinical Oncology). — P. 71s.

23. Singletary S. E. Rating the risk factors for breast cancer // Ann. Surg. — 2003. — Vol.237. — P.474–482.

24. Stratton M. R., Rahman N. The emerging landscape of breast cancer susceptibility. Nat. Genet. 2008; 40 (1): 17–22.

25. Alexandra S. Weiner, Uljana A. Boyarskikh, Elena N. Voronina, Inna A. Selezneva, Tatiana V. Sinkina, Alexandr F. Lazarev, Valentina D. Petrova, Maxim L. Filipenko Polymorphisms in the folate-metabolizing genes MTR, MTRR, and CBS and breast cancer risk / Cancer Epidemiology // The International Journal of Cancer Epidemiology, Detection, and Prevention journal home page: www. cancerepidemiology.net G Model CANEP-390; No.of Pages 6.